Research & Development
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Flu Vaccine Leader Sanofi Joins Fight Against COVID-19
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Clinical Trials
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Clinical Trials
Teva’s Austedo Fails In Tourette’s Syndrome
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Incyte Ready To Go For Approval Of Topical Ruxolitinib In Atopic Dermatitis
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Basilea Stresses Derazantinib's FGFR Kinase Differentiation
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Helixmith Mods Engensis Trial Plans As Probe Unravels PK Anomalies
After probing pharmacokinetic data flaws in the first US Phase III study for its gene therapy Engensis, Korea's Helixmith concludes that these stemmed from clinical operation issues. As a result, it admits a failure to meet the primary endpoint but is still moving forward with new trials given signals of efficacy and safety in an extended study.
Interview: Spain's Sanifit Set For Significant 2020
The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.
Ipsen Upbeat Despite Palovarotene Pain
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.
Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Approvals
Interview: Novartis's Big Hopes For Beovu
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
Pipeline Watch: Phase III Readouts In Fabry Disease, Uterine Fibroids
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
Pipeline Watch: Approvals For Peanut Allergy, Pandemic Flu, Vaccines
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Readouts In Atopic Dermatitis, Ischemic Stroke
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
US Approval For Peanut Allergy Therapy Palforzia
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.